NKTR

Business Context and Reporting Period

Company: Nektar Therapeutics (formerly Inhale Therapeutic Systems, Inc.)
Reporting Period: Fiscal year ended December 31, 2003
Business Model: Nektar is a drug delivery technology company operating three platforms: Advanced PEGylation, Pulmonary Technology, and Supercritical Fluid (SCF) Technology. The company generates revenue primarily through collaborative agreements with pharmaceutical and biotechnology partners, receiving milestone payments, manufacturing fees, and royalties. It does not currently market products independently.

Key Financial Metrics (Year Ended Dec 31, 2003)

Revenue Composition: Contract research revenue was $79.0 million (74% of total), and product sales were $27.3 million (26% of total). Pfizer accounted for 59% of total revenue.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 12% year-over-year, driven by increased product sales (up 48%) and higher activity under collaboration agreements with Chiron and Solvay.
• Improved Profitability: Net loss narrowed significantly from $107.5 million in 2002 to $46.7 million in 2003. This improvement was largely due to a $31.2 million gain on debt extinguishment resulting from the repurchase and exchange of convertible notes.
• Expense Reduction: R&D expenses decreased 16% due to a workforce reduction completed in late 2002 and deferred spending. General and administrative expenses decreased 15% for similar reasons.
• Debt Restructuring: The company issued $110.0 million in new 3% convertible notes due 2010 and exchanged $87.9 million of older 3.5% notes for new 3% notes, extending maturities and reducing interest costs.

Guidance, Outlook, and Risks

Outlook: Management expects to continue incurring substantial losses for the next few years as it expands R&D and commercial manufacturing. The company forecasts sufficient cash to meet net operating expense requirements for at least the next two years but anticipates needing additional capital to repay long-term debt obligations maturing in 2006, 2007, and 2010.

Key Catalysts:

• Exubera (Inhaled Insulin): In March 2004, Pfizer and Aventis announced the European Medicines Evaluation Agency (EMEA) accepted a marketing authorization application. U.S. filing timing remains at Pfizer's discretion.
• Macugen: Partner Eyetech plans to file a New Drug Application (NDA) in the second half of 2004 following positive Phase III data.

Material Risks:

• Partner Dependence: The company relies on partners (notably Pfizer) for regulatory approval and commercialization. Termination of the Pfizer collaboration would significantly harm financial results.
• Liquidity & Debt: With $360 million in convertible debt and no investment-grade credit rating, the company faces refinancing risk. Conversion of debt to equity is unlikely at current stock prices, necessitating cash repayment or new financing.
• Regulatory Uncertainty: Delays in FDA/EMEA approval for Exubera or other pipeline products could delay revenue recognition and increase costs.

Investor Verification Checklist

• Debt Maturity Profile: Verify the company's ability to refinance or repay $183 million in debt due in 2007 and $169 million due in 2010 given current cash burn rates.
• Exubera Regulatory Status: Monitor Pfizer's decision on the U.S. NDA filing timeline and any FDA feedback regarding pulmonary function data.
• Revenue Concentration: Assess the risk of losing 59% of revenue if the Pfizer collaboration is altered or terminated.
• Capitalization: Review the dilutive impact of outstanding convertible notes and stock options (approx. 36.6 million shares reserved) on future equity value.
• Manufacturing Scale-up: Confirm progress on commercial-scale manufacturing capabilities for pulmonary devices and powders, which are critical for Exubera launch.